SYNTA PHARMACEUTIC (NASDAQ:SNTA)
3.82
-0 (-0%)
| SYNTA PHARMACEUTIC (NASDAQ:SNTA) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $3.82 | 52 Week High | $9.55 | ||
| Open | $3.81 | 52 Week Low | $1.20 | ||
| Day High | $3.85 | P/E | 2.16 | ||
| Day Low | $3.75 | EPS | $1.77 | ||
| Volume | 34,094 | ||||
| More SNTA Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| BARE | 3 | GSK | 3 |
| C | 3 | SOMX | 2 |
| NYFX | 2 | BITI | 2 |
| BCSI | 2 | WFC | 2 |
| OUTD | 2 | CVA | 2 |
| OVTI | 2 | NPSP | 2 |
Entities who have mentioned SNTA
- Citi | View Related Stories »
- Lazard | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Banc of America | View Related Stories »
- Wachovia | View Related Stories »
- JPMorgan | View Related Stories »
- Goldman Sachs | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Credit Suisse | View Related Stories »
- Robert W Baird | View Related Stories »
- Crude Oil | View Related Stories »
- RBC Capital | View Related Stories »
- Trading Radar | View Related Stories »
- Bankruptcy | View Related Stories »
- Dividend | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- After-Hours Movers | View Related Stories »
- Twitter | View Related Stories »
- Goldman Sachs Conviction Sell List | View Related Stories »
- KeyBanc | View Related Stories »
- UBS | View Related Stories »
- Morgan Stanley | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- Friedman, Billings, Ramsey | View Related Stories »
- Jim Cramer | View Related Stories »
View All Major News StreetInsider.com Major News for SNTA
- Synta Pharmaceuticals Corp. (SNTA) Tops EPS View, Misses Revenue Estimates
- Synta Pharmaceuticals (SNTA) Said SYMMETRYSM Trial Did Not Achieve Statistical Significance
- Synta Pharma (SNTA) Reports Better-Than Expected Q4 Loss of $0.77
View All ReportsStreetInsider.com Reports on SNTA
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Synta Pharmaceuticals Corp. (SNTA) Tops EPS View, Misses Revenue Estimates
- Synta Pharmaceuticals (SNTA) Names Dr. Vojo Vukovic as Chief Medical Officer
- Synta (SNTA) and GlaxoSmithKline End Collaboration
- Unusual 11 Mid-Day Movers 6/1: FEP, PMI, GPRE, ETWC Higher; ABIO, SNTA, ABII, EDZ Lower
View All Press ReleasesCompany Press Releases on SNTA
- Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090
- Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
- Synta Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
- Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results
StreetInsider Reports on SNTA by Category
View All BlogsBlogs on SNTA
- Synta Pharmaceuticals Corp. Q3 2009 Earnings Call Transcript
- Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
- Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up
- Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
- Morphosys: A Biotech Rule Breaker (Part 2)
Comments on recent SNTA articles
Comments on SNTA
No comments are currently available.
on Mar 2, 2009
at 05:10 PM snta I expect snta to be upgraded to buy very soon and stock to move to $5.00 by 3/30/09
Article: Synta (SNTA) Suspends Trial Due To Higher Deaths